Candel Therapeutics (CADL) Total Liabilities (2020 - 2025)

Candel Therapeutics has disclosed Total Liabilities across 6 years of filings, most recently posting $73.3 million for Q4 2025.

• Total Liabilities for Q4 2025 came in at $73.3 million, up 80.75% year-over-year; the trailing twelve-month figure through Dec 2025 was $73.3 million (up 80.75% YoY), and the FY2025 annual result was $73.3 million, up 80.75% from the prior year.
• Total Liabilities came in at $73.3 million for Q4 2025 at Candel Therapeutics, up from $13.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $73.3 million in Q4 2025 to a low of $13.5 million in Q3 2025.
• The 5-year median for Total Liabilities is $28.2 million (2023), against an average of $30.9 million.
• Across the five-year window, Total Liabilities surged 122.55% in 2021 and tumbled 63.36% in 2025, its largest moves.
• Candel Therapeutics' Total Liabilities stood at $25.1 million in 2021, then advanced by 19.58% to $30.0 million in 2022, then declined by 5.07% to $28.5 million in 2023, then soared by 42.46% to $40.5 million in 2024, then surged by 80.75% to $73.3 million in 2025.
• The last three Total Liabilities figures came in at $73.3 million (Q4 2025), $13.5 million (Q3 2025), and $15.8 million (Q2 2025), per Business Quant data.